Clinical Trials Logo

Filter by:
NCT ID: NCT05171075 Recruiting - Pulmonary Embolism Clinical Trials

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

MAGNOLIA
Start date: September 27, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

NCT ID: NCT05171049 Recruiting - Pulmonary Embolism Clinical Trials

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

ASTER
Start date: May 5, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

NCT ID: NCT05170204 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Start date: November 1, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.

NCT ID: NCT05169515 Recruiting - Clinical trials for Non-Hodgkin Lymphoma

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Start date: October 26, 2022
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 or CC-99282) in participants with B-cell NHL.

NCT ID: NCT05169333 Recruiting - Clinical trials for Cardiovascular Diseases

The Oxford Risk Factors And Non-Invasive Imaging Study

ORFAN
Start date: February 23, 2016
Phase:
Study type: Observational [Patient Registry]

ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.

NCT ID: NCT05166564 Recruiting - Clinical trials for Cognitive Impairment

The PROtein Enriched MEDiterranean Diet and EXercise Trial for Older Adults at Risk of Undernutrition

PROMED-EX
Start date: January 18, 2022
Phase: N/A
Study type: Interventional

PROMED-EX is a single-blind, parallel group randomised controlled trial to determine the effect of a PROtein enriched MEDiterranean diet (PROMED) in comparison to a PROtein enriched MEDiterranean diet and EXercise (PROMED-EX) intervention, or standard care on the nutritional status and cognitive performance of older undernourished adults with subjective cognitive decline.

NCT ID: NCT05166161 Recruiting - Phenylketonuria Clinical Trials

A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria

Start date: February 14, 2022
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the long-term safety of PTC923 in participants with phenylketonuria, and to evaluate the changes from baseline in dietary phenylalanine (Phe)/protein consumption.

NCT ID: NCT05165433 Recruiting - Metastatic Cancer Clinical Trials

Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)

FORTIFY
Start date: April 13, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-350A in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours.

NCT ID: NCT05165095 Recruiting - Bradycardia Clinical Trials

Clinical Assessment of Essential Remote Monitoring Functions in Pacemakers

CALLIOPE
Start date: March 25, 2022
Phase:
Study type: Observational

The purpose of the clinical investigation is to document the safety and the performances of the remote monitoring functions of the ALIZEA, BOREA and CELEA pacemakers, i.e. the RAAT, the RVAT and the remote alerts.

NCT ID: NCT05164939 Recruiting - Severe Asthma Clinical Trials

Precision Medicine Intervention in Severe Asthma (PRISM) Study

Start date: May 1, 2020
Phase:
Study type: Observational

The Korea-UK Precision Medicine Intervention in Severe Asthma (PRISM) study aims to identify molecular phenotypes of severe asthma by analyzing multi-omics data including genomics, epigenomics, transcriptomics, proteomics, metagenomics, and metabolomics.